Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases

被引:224
作者
Hoelscher, Christian [1 ]
机构
[1] Univ Lancaster, Fac Hlth & Med, Div Biomed & Life Sci, Lancaster LA1 4YQ, England
关键词
neurodegeneration; Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis; stroke; ischaemia; incretins; multiple sclerosis; glucagon-like peptide 1; GLUCAGON-LIKE PEPTIDE-1; PROGENITOR-CELL PROLIFERATION; TYPE-2; DIABETES-MELLITUS; GROWTH-FACTOR-I; ALZHEIMERS-DISEASE; INTRANASAL INSULIN; AMYLOID-BETA; SYNAPTIC PLASTICITY; RECEPTOR AGONISTS; PLASMA-MEMBRANE;
D O I
10.1530/JOE-13-0221
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incretin hormone glucagon-like peptide 1 (GLP-1) has many effects in the body. It is best known for the 'incretin effect', facilitating insulin release from the pancreas under hyperglycaemic conditions. Building on this, GLP-1 mimetics have been developed as a treatment for type 2 diabetes. In the course of monitoring of patients, it has become apparent that GLP-1 mimetics have a range of other physiological effects in the body. In preclinical trials, a substantial body of evidence has been built that these mimetics have neuroprotective and anti-inflammatory effects. GLP-1 also has very similar growth-factor-like properties to insulin, which is presumably the underlying basis of the neuroprotective effects. In preclinical studies of Alzheimer's disease (AD), Parkinson's disease (PD), stroke and other neurodegenerative disorders, it has been shown that most GLP-1 mimetics cross the blood-brain barrier and show impressive neuroprotective effects in numerous studies. In animal models of AD, GLP-1 mimetics such as exendin-4, liraglutide and lixisenatide have shown protective effects in the CNS by reducing beta-amyloid plaques, preventing loss of synapses and memory impairments, and reducing oxidative stress and the chronic inflammatory response in the brain. In animal models of PD, exendin-4 showed protection of dopaminergic neurons in the substantia nigra and prevention of dopamine loss in the basal ganglia while preserving motor control. These encouraging findings have spawned several clinical trials, some of which have shown encouraging initial results. Therefore, GLP-1 mimetics show great promise as a novel treatment for neurodegenerative conditions.
引用
收藏
页码:T31 / T41
页数:11
相关论文
共 99 条
[21]  
CRAFT S, 2010, ICAD C HAW USA
[22]   Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment [J].
Craft, Suzanne .
CURRENT ALZHEIMER RESEARCH, 2007, 4 (02) :147-152
[23]  
D Kuipers S, 2006, CURR OPIN DRUG DISC, V9, P580
[24]  
de la Monte SM, 2006, J ALZHEIMERS DIS, V9, P167
[25]   Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation [J].
Dozier, Kristopher C. ;
Cureton, Elizabeth L. ;
Kwan, Rita O. ;
Curran, Brian ;
Sadjadi, Javid ;
Victorino, Gregory P. .
PEPTIDES, 2009, 30 (09) :1735-1741
[26]   The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].
Drucker, Daniel J. ;
Nauck, Michael A. .
LANCET, 2006, 368 (9548) :1696-1705
[27]   Glucagon-like peptide-1 receptor is involved in learning and neuroprotection [J].
During, MJ ;
Cao, L ;
Zuzga, DS ;
Francis, JS ;
Fitzsimons, HL ;
Jiao, XY ;
Bland, RJ ;
Klugmann, M ;
Banks, WA ;
Drucker, DJ ;
Haile, CN .
NATURE MEDICINE, 2003, 9 (09) :1173-1179
[28]  
Egefjord L, 2012, DAN MED J, V59
[29]   Lixisenatide: First Global Approval [J].
Elkinson, Shelley ;
Keating, Gillian M. .
DRUGS, 2013, 73 (04) :383-391
[30]   Intranasal Insulin as a Treatment for Alzheimer's Disease: A Review of Basic Research and Clinical Evidence [J].
Freiherr, Jessica ;
Hallschmid, Manfred ;
Frey, William H., II ;
Bruenner, Yvonne F. ;
Chapman, Colin D. ;
Hoelscher, Christian ;
Craft, Suzanne ;
De Felice, Fernanda G. ;
Benedict, Christian .
CNS DRUGS, 2013, 27 (07) :505-514